IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria

Journal of the American Society of Nephrology

Volumn 18, Issue 6, 2007, Pages 1880-1888

  Coppo, Rosanna ^a   Peruzzi, Licia ^a   Amore, Alessandro ^a   Piccoli, Antonio ^b   Cochat, Pierre ^c   Stone, Rosario ^d   Kirschstein, Martin ^e   Linné, Tommy ^f  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e ALLGEMEINES KRANKENHAUS CELLE   (Germany)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADOLESCENT; ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENDER; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 34249897747     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006040347     Document Type: Article

References (28)

1. Woo KT, Lau YK, Wong KS, Chiang GS: ACEI/ATRA therapy decreases proteinuria by improving glomerular perselectivity in IgA nephritis. Kidney Int 58: 2485-2489, 2000
2. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F. Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
3. Coppo R, Amore A, Hogg R, Emancipator S: Idiopathic nephropathy with IgA deposits. Pediatr Nephrol 15: 139-150, 2000
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: N Engl J Med 334: 939-945, 1996
5. The GISEN Group: Randomised placebo controlled trial of effect of ramipril on decline in glomerular rate of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
6. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeu D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
7. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemiologici in Nefrologia (Gisen). J Am Soc Nephrol 11: 88-96, 2000
8. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23: 247-254, 1994
9. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, Sasdelli M, Zuccala A, Zucchelli P: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 9: 255-269, 1994
10. Coppo R, Peruzzi L. Moderately proteinuric IgA nephropathy in the young. In: Biomedical Health Research, Vol. 44, Amsterdam, IOS Press, 2000, pp 18-28
11. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
12. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34: 571-590, 1987
13. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446, 1997
14. Update on the 1987 Task Force Report on high blood pressure in children and adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 98: 649-658, 1996
15. Schaefer F, Georgi M, Wuhl E, Scharer K: Body mass index and percentage fat mass in healthy German schoolchildren and adolescents. Int J Obes Relat Metab Disord 22: 461-469, 1998
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003
17. Wuhl E, Witte K, Soergel M, Mehls O, Schaefer F; German Working Group on Pediatric Hypertension: Distribution of 24-h ambulatory blood pressure in children: Normalized reference values and role of body dimensions. J Hypertens 20: 1995-2007, 2002
18. Reddan DN, Owen WF Jr: IgA nephropathy and inhibitors of the renin angiotensin system: Is reduction in proteinuria adequate proof of efficacy? Am J Kidney Dis 38: 182-185, 2001
19. Dillon JJ: Treating IgA nephropathy. J Am Soc Nephrol 12: 846-847, 2001
20. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
21. Yoshikawa N, Tanaka R, Iijima K: Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 16: 446-457, 2001
22. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 49: 578-597, 1996
23. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33: 851-856, 1999
24. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, Peruzzi L, Piccoli G, De Filippi PG: Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 21: 593-602, 1993
25. Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, Graziotto R, Furci L, Modena F, Bernich P, Albertazzi A, D'Angelo A, Maschio G: Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 64: 149-159, 2003
26. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003
27. Hogg RJ: Prognostic indicators and treatment of childhood IgA nephropathy. Contrib Nephrol 111: 194-200, 1995
28. Fassbinder W, Brunner FP, Brynger H, Ehrich JH, Geerlings W, Raine AE, Rizzoni G, Selwood NH, Tufveson G, Wing AJ: Combined report on regular dialysis and transplantation in Europe XX, 1989. Nephrol Dial Transplant 6[Suppl 1]: 5-35, 1991